Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx
Seegnal Inc. (TSXV: SEGN) (“Seegnal” or the “Company”), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced the formation of a dedicated Strategic Commercialization Team led by its Chief Executive Officer, and the engagement of CapitaLynx Ltd. (operating as “Arx”) as its investor relations advisor.
Establishment of Strategic Commercialization Team
Seegnal has established a cross-functional Strategic Commercialization Team tasked with accelerating the Company’s go-to-market execution across target healthcare systems and geographies. The team is led directly by the Chief Executive Officer and includes senior members representing clinical affairs, business development, regulatory strategy, and technology integration.
The formation of this team reflects the Company’s transition into a structured commercialization phase following the successful deployment and clinical validation of its medication safety platform at leading healthcare institutions. The team is responsible for managing strategic partnerships, contract negotiations, and revenue-generating deployment pipelines.
“Establishing a dedicated commercialization team is a defining step in Seegnal’s evolution from clinical proof-of-concept to scalable market presence,” said Elad Bibi-Aviv, Chief Executive Officer of Seegnal. “We are executing with clarity and urgency, and our team has the operational depth to convert our clinical track record into sustained commercial momentum.”
Engagement of Arx as Investor Relations Advisor
Pursuant to TSXV Policy 3.4, Seegnal announces that it has engaged CapitaLynx Ltd. (“Arx”) to provide technology-powered investor relations services commencing on April 1, 2026 pursuant to the terms of an investor relations technologies and services agreement dated March 26, 2026 between Seegnal and Arx.
The services to be provided by Arx include: press release and investor materials drafting and optimization; stock and investor monitoring; third-party newswire distribution and reporter targeting; management of an investor relations inbox; and ancillary advisory support relating to capital markets and investor relations matters.
The agreement has an initial non-cancellable term of three (3) months (the “Initial Term”), during which the Company is required to pay a aggregate fee of US$49,500 (US$16,500 per month), followed by automatic quarterly renewals at a fee of US$16,500 per month (US$49,500 per quarter). After the Initial Term the agreement shall automatically renew for successive quarterly periods, each consisting of three (3) months and either party may terminate the agreement by providing no less than thirty days prior written notice.
Arx is an arm’s-length party to the Company. Arx does not currently hold any securities of Seegnal Inc.
About Seegnal Inc.
Seegnal Inc. (TSXV: SEGN) is a global leader in clinical decision support, applying patient-centric medication safety standards to improve outcomes…
